These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8082411)
21. Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. Tzatzarakis MN; Tsatsakis AM; Charvalos E; Vakalounakis D J Environ Sci Health B; 2001 May; 36(3):331-40. PubMed ID: 11411855 [TBL] [Abstract][Full Text] [Related]
22. Rifampin Enhances the Activity of Amphotericin B against Fusarium solani Species Complex and Aspergillus flavus Species Complex Isolates from Keratitis Patients. He Y; Zhou L; Gao C; Han L; Xu Y Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115342 [TBL] [Abstract][Full Text] [Related]
23. The antibiotic polymyxin B exhibits novel antifungal activity against Fusarium species. Hsu LH; Wang HF; Sun PL; Hu FR; Chen YL Int J Antimicrob Agents; 2017 Jun; 49(6):740-748. PubMed ID: 28433743 [TBL] [Abstract][Full Text] [Related]
24. Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole. Sekhon AS; Padhye AA; Garg AK; Hamir Z Chemotherapy; 1992; 38(3):169-73. PubMed ID: 1324830 [TBL] [Abstract][Full Text] [Related]
25. Pentamidine is active in vitro against Fusarium species. Lionakis MS; Lewis RE; Samonis G; Kontoyiannis DP Antimicrob Agents Chemother; 2003 Oct; 47(10):3252-9. PubMed ID: 14506038 [TBL] [Abstract][Full Text] [Related]
26. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Azor M; Gené J; Cano J; Guarro J Antimicrob Agents Chemother; 2007 Apr; 51(4):1500-3. PubMed ID: 17220423 [TBL] [Abstract][Full Text] [Related]
27. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Spader TB; Venturini TP; Cavalheiro AS; Mahl CD; Mario DN; Lara VM; Santurio J; Alves SH Mycoses; 2011 Mar; 54(2):131-6. PubMed ID: 19780977 [TBL] [Abstract][Full Text] [Related]
28. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Córdoba S; Rodero L; Vivot W; Abrantes R; Davel G; Vitale RG Int J Antimicrob Agents; 2008 Feb; 31(2):171-4. PubMed ID: 18054469 [TBL] [Abstract][Full Text] [Related]
29. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Arias A; Arévalo MP; Andreu A; Rodríguez C; Sierra A Chemotherapy; 1996; 42(2):107-11. PubMed ID: 8697885 [TBL] [Abstract][Full Text] [Related]
31. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Guilhermetti E; Takahachi G; Shinobu CS; Svidzinski TI Int J Dermatol; 2007 Aug; 46(8):822-6. PubMed ID: 17651164 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the inhibitory effect of amphotericin B on the apical growth of F. solani using the BioCell-Tracer system. Teixeira AB; Moretti ML; Machado HC; Nishimura K; Taguchi H; Schreiber AZ Mycoses; 2007 May; 50(3):183-8. PubMed ID: 17472613 [TBL] [Abstract][Full Text] [Related]
33. [Synergic effect of 5-fluorocytosine and imidazole derivatives against yeast strains resistant to 5-fluorocytosine]. Mary C; Goudard M; Blancard A; Quilici M; Regli P Ann Biol Clin (Paris); 1989; 47(9):546-9. PubMed ID: 2558599 [TBL] [Abstract][Full Text] [Related]
34. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system]. Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673 [TBL] [Abstract][Full Text] [Related]
35. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. Espinel-Ingroff A J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410 [TBL] [Abstract][Full Text] [Related]
36. [Activity of itraconazole against clinical isolates of Aspergillus spp. and Fusarium spp. determined by the M38-P NCCLS method]. Carrillo-Muñoz AJ; Quindós G; Ruesga M; Brió S; del Valle O; Rodríguez V; Hernández-Molina JM; Cantón E; Pemán J; Santos P Rev Esp Quimioter; 2001 Sep; 14(3):281-5. PubMed ID: 11753450 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of voriconazole against selected fungi. McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841 [TBL] [Abstract][Full Text] [Related]
38. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Xie L; Zhai H; Zhao J; Sun S; Shi W; Dong X Am J Ophthalmol; 2008 Aug; 146(2):260-265. PubMed ID: 18547535 [TBL] [Abstract][Full Text] [Related]
39. Identification and antifungal sensitivity of Fusarium species isolated from piscine hosts. Khangembam VC; Thakuria D; Tandel RS; Pant V; Pandey N; Pandey PK Dis Aquat Organ; 2024 Aug; 159():117-126. PubMed ID: 39206606 [TBL] [Abstract][Full Text] [Related]
40. In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Taj-Aldeen SJ; Salah H; Al-Hatmi AM; Hamed M; Theelen B; van Diepeningen AD; Boekhout T; Lass-Flörl C Diagn Microbiol Infect Dis; 2016 Aug; 85(4):438-43. PubMed ID: 27312690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]